The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
if you only introduce a whole bunch of mutations to 10% of the tumor you're you might generate a new immune response you might kick the tumor over the edge either by having so many mutations that it all under goes program cell death or it now finally Rises to the level of detection but that's not sufficient enough for the across the clear the rest yeah it won't clear the rest of the tumors
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.